The Association Between Variability in Tacrolimus Trough Levels and Posttransplant Diabetes Mellitus in Thai Kidney Transplant Patients
Suthabordee Muongmee, Pitchamon Inkong, Pamila Tasanavipas, Manat Pongchaidecha, Chalermlap Nadee, Viroon Mavichak, Daraporn RungpraiBackground.
Tacrolimus (TAC) trough-level variability has been associated with patient outcomes and renal graft survival. However, its relationship with posttransplant diabetes mellitus (PTDM) remains unclear. This study aims to evaluate the association between the coefficient of variation (CV) of TAC (TAC-CV) and the incidence of PTDM within the first year after kidney transplantation (KT).
Methods.
A multicenter retrospective study was conducted on 516 Thai KT patients who received TAC-based immunosuppressive regimens from 2011 to 2020, with a 1-y post-KT follow-up period. TAC-CV was calculated for the 0–12 mo post-KT period, and optimal cutoff values were determined using receiver operating characteristic analysis.
Results.
Of the 516 patients, 208 (40.31%) developed PTDM, whereas 308 (59.69%) did not during the first year post-KT. Significant associations were found between TAC-CV and PTDM throughout the study period (
Conclusions.
These findings suggest that TAC-CV may serve as a valuable marker for identifying patients at high risk of PTDM and may aid in its prevention and effective management in KT recipients.